Our findings on DLBCL cell lines and DLBCL xenograft murine model show PHB involvement in ERK-MNK-eIF4E and Akt pathways and strongly suggest that targeting PHBs using flavaglines may be a potential therapeutic strategy in DLBCL. Here, AKT1 is linked to diffuse large B-cell lymphoma.